John Bostjancic Net Worth

The estimated Net Worth of John J. Bostjancic is at least $1.97 Million dollars as of 1 January 2023. Mr. Bostjancic owns over 5,575 units of SeaSpine Corp stock worth over $1,009,752 and over the last 9 years he sold SPNE stock worth over $0. In addition, he makes $965,133 as Chief Financial Officer, Senior Vice President, and Treasurer at SeaSpine Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Bostjancic SPNE stock SEC Form 4 insiders trading

John has made over 9 trades of the SeaSpine Corp stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 5,575 units of SPNE stock worth $53,186 on 1 January 2023.

The largest trade he's ever made was exercising 33,469 units of SeaSpine Corp stock on 1 January 2020 worth over $319,294. On average, John trades about 3,456 units every 96 days since 2015. As of 1 January 2023 he still owns at least 105,844 units of SeaSpine Corp stock.

You can see the complete history of Mr. Bostjancic stock trades at the bottom of the page.

John Bostjancic biography

John J. Bostjancic serves as Chief Financial Officer, Senior Vice President, Treasurer of the Company. Prior to this, Mr. Bostjancic served as acting chief financial officer of the SeaSpine business within Integra LifeSciences Holdings Corporation since December 2014. Prior to that, he was Integra’s senior vice president of global supply chain from February 2012 through November 2014, where he was responsible for global planning, kitting, distribution, logistics and customer service functions and led the project team implementing the U.S. Food and Drug Administration’s “unique device identifier” rule in 2014. From 2008 until January 2012, Mr. Bostjancic was senior vice president of financial planning & analysis at Integra. Since Mr. Bostjancic joined Integra in 1999, he held roles of increasing responsibility in the finance organization, including corporate controller from 2003 through 2006. Before joining Integra, Mr. Bostjancic was a manager in the accounting standards team at Merck & Co., Inc., a publicly traded global health care company, from 1998 through 1999 and worked in the business assurance organization at PricewaterhouseCoopers from 1993 through 1998. He received his B.S. in accounting from the College of New Jersey.

What is the salary of John Bostjancic?

As the Chief Financial Officer, Senior Vice President, and Treasurer of SeaSpine Corp, the total compensation of John Bostjancic at SeaSpine Corp is $965,133. There are 2 executives at SeaSpine Corp getting paid more, with Keith Valentine having the highest compensation of $1,840,570.

How old is John Bostjancic?

John Bostjancic is 49, he's been the Chief Financial Officer, Senior Vice President, and Treasurer of SeaSpine Corp since 2018. There are 15 older and 4 younger executives at SeaSpine Corp. The oldest executive at SeaSpine Holdings Corp is Keith Bradley, 75, who is the Independent Director.

What's John Bostjancic's mailing address?

John's mailing address filed with the SEC is 26061 MERIT CIR, #102, LAGUNA HILLS, CA, 92653.

Insiders trading at SeaSpine Corp

Over the last 9 years, insiders at SeaSpine Corp have traded over $2,659,931 worth of SeaSpine Corp stock and bought 297,805 units worth $3,591,897 . The most active insiders traders include Stuart Essig, Richard E Caruso, and Keith Valentine. On average, SeaSpine Corp executives and independent directors trade stock every 39 days with the average trade being worth of $151,762. The most recent stock trade was executed by John J. Winge on 1 January 2023, trading 4,868 units of SPNE stock currently worth $46,441.

What does SeaSpine Corp do?

SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine's orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine's spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in both orthobiologic sciences and spinal implants product development allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide.

Complete history of Mr. Bostjancic stock trades at Orthofix Medical Inc, SeaSpine Corp, and Sonendo

SeaSpine Corp executives and stock owners

SeaSpine Corp executives and other stock owners filed with the SEC include:

• Keith Valentine,
  President, Chief Executive Officer, Director
• Keith C. Valentine,
  Pres, CEO & Director
• John Bostjancic,
  Chief Financial Officer, Senior Vice President, Treasurer
• Tyler Lipschultz,
  Senior Vice President, Orthobiologics and Business Development
• Patrick Keran,
  Vice President, General Counsel, Secretary
• John Winge,
  Vice President of Sales
• John J. Bostjancic,
  Sr. VP, CFO & Treasurer
• Patrick L. Keran,
  Sr. VP, Gen. Counsel & Sec.
• Dr. Beau Standish P.Eng., Ph.D.,
  Pres of Enabling Technologies
• Kimberly Commins-Tzoumakas,
  Independent Director
• Renee Gaeta,
  Independent Director
• Kirtley Stephenson,
  Independent Non-Executive Chairman of the Board
• Stuart Essig,
  Lead Independent Director
• Michael Fekete,
  Independent Director
• Keith Bradley,
  Independent Director
• John Henneman,
  Independent Director
• Dennis Cirino,
  Senior Vice President, Global Spinal Systems
• Hollis Winkler,
  Sr. VP of HR
• Patrick L. Keran J.D.,
  Sr. VP, Gen. Counsel & Sec.
• Dr. Frank Vizesi,
  Chief Scientific Officer
• Shaeffer Bannigan,
  Sr. Director of Product Devel.
• Paul Benny,
  VP, Corp. Controller, Assistant Treasurer & Assistant Sec.
• Dr. Beau Standish Ph.D.,
  Pres of Enabling Technologies
• Dennis L. Cirino,
  Sr. VP of Global Spinal Systems
• Tyler P. Lipschultz,
  Sr. VP of Orthobiologics & Bus. Devel.
• John J. Winge,
  VP of Sales
• Carrie Mendivil,
  Head of Investor Relations
• James M Sullivan,
  Director
• Cheryl R Blanchard,
  Director
• Brian D. Baker,
  VP, Global Operations
• Richard E Caruso,
  10% owner
• Shweta Maniar,
  Director
• Life Sciences Corp Integra ...,
  
• Beau Standish,
  President, Enabling Tech
• Angela Steinway,
  Director